Related Experiment Video

Updated: Aug 10, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

Mateusz Koptyra1, Rafal Falinski, Michal O Nowicki

  • 1Department of Microbiology and Immunology, School of Medicine and the Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19140, USA.

Blood
|March 11, 2006
PubMed

Insights

BCR/ABL kinase generates reactive oxygen species (ROS), causing DNA damage and imatinib resistance mutations. Antioxidants reduce these mutations, suggesting ROS inhibition can enhance imatinib effectiveness in leukemia treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Imatinib mesylate (IM) is a targeted therapy for chronic myeloid leukemia (CML).
  • Resistance to IM often arises from mutations in the BCR/ABL kinase domain.
  • The role of oxidative stress in BCR/ABL-mediated mutagenesis remains incompletely understood.

Purpose of the Study:

  • To investigate the role of reactive oxygen species (ROS) in BCR/ABL-induced mutagenesis.
  • To determine if ROS inhibition can reduce imatinib resistance.
  • To evaluate the combined effect of IM and antioxidants.

Main Methods:

  • Assessing ROS production in BCR/ABL-expressing cells.
  • Analyzing DNA mutations in the BCR/ABL kinase domain.
  • Treating leukemia cells with antioxidants (PDTC, NAC, VE) and IM.
  • Evaluating the frequency of IM resistance mutations.

Main Results:

  • BCR/ABL kinase activity stimulates ROS production, leading to oxidative DNA damage and kinase domain mutations.
  • Mutations observed were predominantly A/T to G/C and G/C to A/T transitions, consistent with clinical observations.
  • Antioxidant treatment significantly decreased mutagenesis and the frequency of IM resistance.
  • A BCR/ABL(Y177F) mutant with reduced ROS production showed decreased mutagenesis.
  • Combined IM and antioxidant therapy demonstrated a superior antimutagenic effect.

Conclusions:

  • BCR/ABL-driven ROS production is a key mechanism for generating IM resistance mutations.
  • Inhibiting ROS with antioxidants can reduce mutagenesis and overcome IM resistance.
  • Combined antioxidant and IM therapy holds promise for improving CML treatment outcomes.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...